WCLC 2025 - Posters & ePosters-EP.13.11 Real-World Survival Data Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors

EP.13.11 Real-World Survival Data Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors

Back to course

Pdf Summary

This retrospective single-center study examined real-world survival trends in 452 patients with extensive-stage small-cell lung cancer (ES-SCLC) over 25 years (1999–2023), focusing on the impact of immune checkpoint inhibitors (ICIs). Patients were grouped into five diagnosis periods: A (1999–2003), B (2004–2008), C (2009–2013), D (2014–2018), and E (2019–2023). Data showed incremental improvements in median overall survival (mOS) over time, with Period E demonstrating the longest mOS at 13.6 months and the highest 2-year survival rate (29.3%).<br /><br />ICI treatment, introduced only in Periods D and E, was administered to 14.1% and 73.1% of patients respectively, showing a significant survival benefit. Patients receiving ICIs had a mOS of 15.2 months versus 11.8 months in those not treated with ICIs (p=0.005). Multivariate analysis identified performance status (2-4 or unknown), history of platinum doublet chemotherapy, and ICI treatment as independent factors influencing survival. Specifically, ICI treatment was associated with a 32% reduction in the hazard of death (HR 0.68, p=0.005).<br /><br />Patient characteristics were broadly similar across periods, though there was a slight increase in female patients and those under 75 years in later periods. The majority were smokers and had good performance status (0-1).<br /><br />The study concludes that survival in ES-SCLC has improved modestly over 25 years, and the introduction of ICIs in recent years appears to contribute significantly to improved overall survival in real-world clinical practice. These findings support the growing role of ICIs as a standard component of care in ES-SCLC.

Asset Subtitle

Ryo Ariyasu

Meta Tag

Speaker Ryo Ariyasu

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive-stage small-cell lung cancer

ES-SCLC

immune checkpoint inhibitors

ICIs

overall survival

median overall survival

real-world study

retrospective study

platinum doublet chemotherapy

performance status